Novavax reported $745.56M in Equity Capital and Reserves for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Adamas Pharmaceuticals ADMS:US -4033000 9.97M
Adma Biologics ADMA:US $ 111.59M 0.91M
Agenus AGEN:US $ -228.84M 61.78M
AstraZeneca AZN:LN 15676M 1246M
Astrazeneca AZN:US $ 15676M 1246M
Biocryst Pharmaceuticals BCRX:US $ -106.08M 31.09M
Dynavax Technologies DVAX:US $ 83.38M 16.38M
Genocea Biosciences GNCA:US $ 4.06M 2.29M
Geron GERN:US $ 176.21M 24.96M
GlaxoSmithKline GSK:LN 15426M 49M
Kindred Biosciences KIN:US $ 79.77M 4.02M
Mannkind MNKD:US $ -183.55M 9.93M
Merk MRK:US $ 33294M 6349M
Minerva Neurosciences NERV:US $ 36.17M 9.2M
Moderna Inc MRNA:US 6.7B 2.87B
Novartis NVS:US $ 56771M 2729M
Novavax NVAX:US $ 745.56M 293.56M
Pain Therapeutics PTIE:US $ 276.48M 4.71M
Peregrine Pharmaceuticals PPHM:US $ 44.64M 33.1M
Sarepta Therapeutics SRPT:US $ 485.11M 50.34M
Tg Therapeutics TGTX:US $ 383.13M 62.16M